Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:John_C._Jacobs
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedVaccineFor |
gptkb:COVID-19
influenza |
| gptkbp:focusesOn |
vaccine development
|
| gptkbp:foundedYear |
1987
|
| gptkbp:fullName |
gptkb:Novavax,_Inc.
|
| gptkbp:headquartersLocation |
gptkb:Gaithersburg,_Maryland,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NVAX
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:marketCap |
varies (publicly traded)
|
| gptkbp:notableProduct |
gptkb:Covovax
gptkb:Nuvaxovid |
| gptkbp:numberOfEmployees |
~1500 (2023)
|
| gptkbp:researchInterest |
recombinant nanoparticle vaccines
|
| gptkbp:stockSymbol |
gptkb:NVAX
|
| gptkbp:tradedOn |
gptkb:NASDAQ:NVAX
|
| gptkbp:type |
public
|
| gptkbp:website |
https://www.novavax.com/
|
| gptkbp:bfsParent |
gptkb:Novavax
|
| gptkbp:bfsLayer |
6
|